Crossmark

Nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil for metastatic pancreatic ductal adenocarcinoma following gemcitabine-based therapy. A systematic review and meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1007/s10585-026-10401-5

Published Online: 2026-03-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vitale, Elsa

Rizzo, Alessandro

Maistrello, Lorenza

Sciacovelli, Angela Monica

De Luca, Raffaele

Albano, Anna

Fanizzi, Annarita

Massafra, Raffaella

Lotesoriere, Claudio

Gadaleta-Caldarola, Gennaro

Pisconti, Salvatore

Brunetti, Oronzo
License Information

Text and Data Mining valid from 2026-03-31

Version of Record valid from 2026-03-31
More Information

Article History

Received: 15 January 2026

Accepted: 1 March 2026

First Online: 31 March 2026

Declarations

:

: The authors declare no competing interests.

: The authors affiliated to the IRCCS Istituto Tumori “Giovanni Paolo II”, Bari are responsible for the views expressed in this article, which do not necessarily represent the Institute.

Document is current

Any future updates will be listed below